Advanced search    

Search: authors:"Gavin Giovannoni"

42 papers found.
Use AND, OR, NOT, +word, -word, "long phrase", (parentheses) to fine-tune your search.

Multiple Sclerosis Cerebrospinal Fluid Biomarkers

Disease Markers 0278-0240 Multiple sclerosis cerebrospinal fluid biomarkers Gavin Giovannoni 0 0 Department of Neuroinflammation, Institute of Neurology, University College London , Queen Square

The BRAIN test: a keyboard-tapping test to assess disability and clinical features of multiple sclerosis

Background The BRadykinesia Akinesia INcordination (BRAIN) test is an online keyboard-tapping test previously validated as a sensitive tool for detecting signs of Parkinson’s disease. Objectives To determine whether the BRAIN test can measure disability in MS and identify the presence of pyramidal or cerebellar dysfunction. Methods Kinesia scores (KS, number of key taps in 30 s...

Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells

target, possibly with potential biomarker activity, for future drug development. B cell; Cladribine; Disease-modifying treatment; Deoxycytidine kinase; Multiple sclerosis; Memory B cells - Gavin ... Giovannoni and Klaus Schmierer are joint senior authors. Introduction Multiple sclerosis (MS) is a chronic-inflammatory disorder of the central nervous system leading to accumulating disability. Historically

A Risk Score for Predicting Multiple Sclerosis

Objective Multiple sclerosis (MS) develops as a result of environmental influences on the genetically susceptible. Siblings of people with MS have an increased risk of both MS and demonstrating asymptomatic changes in keeping with MS. We set out to develop an MS risk score integrating both genetic and environmental risk factors. We used this score to identify siblings at extremes...

Multiple sclerosis outpatient future groups: improving the quality of participant interaction and ideation tools within service improvement activities

Background Improving the patient experience is a key focus within the National Health Service. This has led us to consider how health services are experienced, from both staff and patient perspectives. Novel service improvement activities bring staff and patients together to use design-led methods to improve how health services are delivered. The Multiple Sclerosis Outpatient...

Characterisation of tissue-type metabolic content in secondary progressive multiple sclerosis: a magnetic resonance spectroscopic imaging study

Proton magnetic resonance spectroscopy yields metabolic information and has proved to be a useful addition to structural imaging in neurological diseases. We applied short-echo time Spectroscopic Imaging in a cohort of 42 patients with secondary progressive multiple sclerosis (SPMS). Linear modelling with respect to brain tissue type yielded metabolite levels that were...

Mononeuritis multiplex as the first presentation of refractory sarcoidosis responsive to etanercept

Background Several disorders may present with mononeuritis multiplex and the etiological diagnosis can be challenging. Case presentation We report a 42 year-old female who presented with severe lower limb neuropathic pain, asymmetric weakness and sensory impairment and was diagnosed with mononeuritis multiplex. Biopsy showed a granulomatous vasculitic process with eosinophils...

Sustained Effect of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing–Remitting Multiple Sclerosis: 6-Year Interim Results From an Extension of the DEFINE and CONFIRM Studies

Advances in Neurological Disorders. Gavin Giovannoni has received honoraria from Abbvie, Bayer HealthCare, Biogen, Canbex Therapeutics, Five Prime Therapeutics, Genzyme, GlaxoSmithKline, GW Pharma, Merck

Optimizing treatment success in multiple sclerosis

Serono SA for consulting services, speaking and travel support. He serves on advisory boards for Merck Serono SA and Novartis, and has received research grant support from the Italian MS Society. Gavin ... Giovannoni has received compensation for serving as a consultant or speaker for, or has received research support from, AbbVie, Bayer Schering Healthcare, Biogen Idec, Canbex, Eisai, Elan, Five Prime

No Evidence of Disease Activity: Indirect Comparisons of Oral Therapies for the Treatment of Relapsing–Remitting Multiple Sclerosis

, Gary Cutter and Gavin Giovannoni designed the study, interpreted the results, and critically reviewed and approved the manuscript. All named authors meet the ICMJE criteria for authorship for this ... received Consortium of Multiple Sclerosis Centers task orders that involve research for various pharmaceutical organizations. Gavin Giovannoni has received honoraria from Bayer HealthCare, Biogen Idec

Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study

Background Daclizumab is a humanized monoclonal antibody against CD25 that modulates interleukin 2 signaling. The SELECT TRILOGY of clinical studies (SELECT/SELECTION/SELECTED) evaluated the safety and efficacy of daclizumab in patients with relapsing-remitting multiple sclerosis (RRMS). We report the long-term safety and efficacy of daclizumab 150 mg subcutaneous every 4 weeks...

National survey of UK medical students on the perception of neurology

Julia Pakpoor 0 Adam E Handel Giulio Disanto Richard J Davenport Gavin Giovannoni Sreeram V Ramagopalan on behalf of the Association of British Neurologists 0 Oxford University Medical School

A service development study of the assessment and management of fracture risk in Parkinson’s disease

Parkinson’s disease (PD) is associated with an increased risk of fragility fracture. FRAX and Qfracture are risk calculators that estimate the 10-year risk of hip and major fractures and guide definitive investigation for osteoporosis using dual X-ray absorptiometry (DEXA) imaging. It is unclear which PD patients should be considered for fracture risk assessment and whether FRAX...

The Refinement of Genetic Predictors of Multiple Sclerosis

A recent genome wide association study (GWAS) demonstrated that more than 100 genetic variants influence the risk of multiple sclerosis (MS). We investigated what proportion of the general population can be considered at high genetic risk of MS, whether genetic information can be used to predict disease development and how the recently found genetic associations have influenced...

Hospital admissions for vitamin D related conditions and subsequent immune-mediated disease: record-linkage studies

Giovannoni 1 Michael J Goldacre 0 0 Unit of Health-Care Epidemiology, Nuffield Department of Population Health, University of Oxford , Oxford , UK 1 Blizard Institute, Barts and the London School of Medicine

Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis

. The authors had full editorial control of the manuscript and provided their final approval of all content. Conflicts of interest Gavin Giovannoni has received research grant support from Bayer Schering

Integrating multiple oestrogen receptor alpha ChIP studies: overlap with disease susceptibility regions, DNase I hypersensitivity peaks and gene expression

Background A wealth of nuclear receptor binding data has been generated by the application of chromatin immunoprecipitation (ChIP) techniques. However, there have been relatively few attempts to apply these datasets to human complex disease or traits. Methods We integrated multiple oestrogen receptor alpha (ESR1) ChIP datasets in the Genomic Hyperbrowser. We analysed these...

Fingolimod modulates microglial activation to augment markers of remyelination

Introduction Microglial activation in multiple sclerosis has been postulated to contribute to long-term neurodegeneration during disease. Fingolimod has been shown to impact on the relapsing remitting phase of disease by modulating autoreactive T-cell egress from lymph organs. In addition, it is brain penetrant and has been shown to exert multiple effects on nervous system cells...

Bradykinesia-Akinesia Incoordination Test: Validating an Online Keyboard Test of Upper Limb Function

Background The Bradykinesia Akinesia Incoordination (BRAIN) test is a computer keyboard-tapping task that was developed for use in assessing the effect of symptomatic treatment on motor function in Parkinson's disease (PD). An online version has now been designed for use in a wider clinical context and the research setting. Methods Validation of the online BRAIN test was...